FDA approves CYRAMZA® (ramucirumab) for EGFR-mutated non-small cell lung cancer
CYRAMZA in combination with erlotinib was approved as a first-line…
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.